1. Leptomeningeal metastases: A RANO proposal for response criteria
- Author
-
Chamberlain, M.C. (Marc C.), Junck, L. (L.), Brandsma, D. (Dieta), Soffietti, R., Rudà, R. (Roberta), Raizer, J., Boogerd, W. (Willem), Taillibert, S., Groves, M.D. (Morris D.), Le Rhun, E. (Emilie), Walker, J. (Julie), Bent, M.J. (Martin) van den, Wen, P.Y. (Patrick Y.), Jaeckle, K. (K.), Chamberlain, M.C. (Marc C.), Junck, L. (L.), Brandsma, D. (Dieta), Soffietti, R., Rudà, R. (Roberta), Raizer, J., Boogerd, W. (Willem), Taillibert, S., Groves, M.D. (Morris D.), Le Rhun, E. (Emilie), Walker, J. (Julie), Bent, M.J. (Martin) van den, Wen, P.Y. (Patrick Y.), and Jaeckle, K. (K.)
- Abstract
Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all cancers; flow cyto
- Published
- 2017
- Full Text
- View/download PDF